Advertisement News Archives - Page 2517 of 5239 - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

October 1, 2026

Bristol Myers Squibb secures expanded US approval for Camzyos

The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and paediatric patients weighing at least 30kg (66lb).

Bristol Myers Squibb secures expanded US approval for Camzyos